| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | $0 | $0 | $0-100.0% | $1.1M-66.6% | $3.2M |
| Cost of revenue | -$906K | $0 | — | — | — | — |
| Gross Profit | $118K | $0 | — | — | — | — |
| Selling, general and administrative | $4.0M+120.7% | $1.8M+134.4% | $765K-44.8% | $1.4M+30.4% | $1.1M-11.2% | $1.2M |
| Operating loss | -$3.8M-114.1% | -$1.8M-134.4% | -$765K+44.8% | -$1.4M-1475.0% | -$88K-105.4% | $1.6M |
| Interest income | $13K+44.4% | $9K+550.0% | -$2K | — | — | $3K |
| Loss from loans to unconsolidated entities | $0+100.0% | -$524K-1214.9% | $47K+128.8% | -$163K+63.9% | -$451K | — |
| Income (loss) from investments in unconsolidated entities, net | $0-100.0% | $90K+4600.0% | -$2K-112.5% | $16K | — | — |
| Impairment expense - goodwill | -$4.0M | $0 | — | — | — | — |
| Total other expense | -$4.0M-832.9% | -$425K-733.3% | -$51K+65.3% | -$147K+68.4% | -$465K+38.7% | -$759K |
| Loss before income taxes | -$7.8M-251.8% | -$2.2M-171.8% | -$816K+46.8% | -$1.5M-177.2% | -$553K-164.6% | $856K |
| Income tax benefit (provision) | $0-100.0% | $163K | $0+100.0% | -$39K+90.7% | -$420K-230.0% | $323K |
| Net loss | -$7.8M-279.8% | -$2.1M-151.8% | -$816K+48.1% | -$1.6M-61.6% | -$973K-282.6% | $533K |
| Basic and diluted net loss per share attributable to Elite Health Systems Inc. (in dollars per share) | -$0.35-169.2% | -$0.13-44.4% | -$0.09+0.0% | -$0.09+18.2% | -$0.11-257.1% | $0.07 |
| Weighted average common shares outstanding, basic and diluted (in shares) | 22.6M+47.1% | 15.4M+65.6% | 9.3M+18.4% | 7.8M+0.6% | 7.8M+0.0% | 7.8M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.